ATE453647T1 - Adenosin a2a rezeptor antagonisten - Google Patents

Adenosin a2a rezeptor antagonisten

Info

Publication number
ATE453647T1
ATE453647T1 AT02784568T AT02784568T ATE453647T1 AT E453647 T1 ATE453647 T1 AT E453647T1 AT 02784568 T AT02784568 T AT 02784568T AT 02784568 T AT02784568 T AT 02784568T AT E453647 T1 ATE453647 T1 AT E453647T1
Authority
AT
Austria
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT02784568T
Other languages
English (en)
Inventor
Craig Boyle
Samuel Chackalamannil
William Greenlee
Unmesh Shah
Yan Xia
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE453647T1 publication Critical patent/ATE453647T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02784568T 2001-11-30 2002-11-26 Adenosin a2a rezeptor antagonisten ATE453647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30
PCT/US2002/037710 WO2003048165A1 (en) 2001-11-30 2002-11-26 ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE453647T1 true ATE453647T1 (de) 2010-01-15

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784568T ATE453647T1 (de) 2001-11-30 2002-11-26 Adenosin a2a rezeptor antagonisten

Country Status (18)

Country Link
US (1) US6916811B2 (de)
EP (1) EP1448565B1 (de)
JP (2) JP4284182B2 (de)
KR (1) KR20050044593A (de)
CN (1) CN1692116A (de)
AR (1) AR037680A1 (de)
AT (1) ATE453647T1 (de)
AU (1) AU2002346503A1 (de)
CA (1) CA2468649C (de)
DE (1) DE60234951D1 (de)
ES (1) ES2336435T3 (de)
HU (1) HUP0402018A3 (de)
IL (1) IL161716A0 (de)
MX (1) MXPA04005209A (de)
PE (1) PE20030665A1 (de)
TW (1) TW200306837A (de)
WO (1) WO2003048165A1 (de)
ZA (1) ZA200404161B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132006A (en) * 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
HUP0401777A3 (en) 2001-10-15 2008-06-30 Schering Corp 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
ATE353331T1 (de) * 2003-10-28 2007-02-15 Schering Corp Verfahren zur herstellung substituierter 5-amino- pyrazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidin
JP2007514758A (ja) * 2003-12-19 2007-06-07 シェーリング　コーポレイション 医薬組成物
EP2258372B8 (de) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A Antagonisten zur Behandlung von motorischen Störungen
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
DK2320911T3 (da) 2008-08-01 2014-11-03 Eye Therapies Llc Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
EP2379556A1 (de) 2008-12-30 2011-10-26 ArQule, Inc. Substituierte 1h-pyrazolo[3,4-d]pyrimidin-6-aminver?bindungen
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
EP3883576B1 (de) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituierte aminotriazolopyrimidine und amino-triazolopyrazin-adenosinrezeptor-antagonisten, pharmazeutische zusammensetzungen und deren verwendung
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
KR102653800B1 (ko) 2018-11-30 2024-04-01 머크 샤프 앤드 돔 엘엘씨 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
CA3120331A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
EP3999513A4 (de) * 2019-07-17 2022-12-21 Teon Therapeutics, Inc. Adenosin-a2a-rezeptorantagonisten und verwendungen davon
CN112608316B (zh) 2019-07-30 2022-10-21 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类腺苷受体拮抗剂
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es) 1993-07-27 2002-03-16 Kyowa Hakko Kogyo Kk Remedio contra la enfermedad de parkinson.
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
MY132006A (en) * 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
AU2004233334B2 (en) * 2003-04-23 2010-08-12 Merck Sharp & Dohme Corp. 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
ZA200404161B (en) 2005-11-30
HUP0402018A3 (en) 2008-06-30
TW200306837A (en) 2003-12-01
MXPA04005209A (es) 2004-08-19
JP2005511699A (ja) 2005-04-28
US6916811B2 (en) 2005-07-12
HUP0402018A2 (hu) 2005-02-28
US20030212059A1 (en) 2003-11-13
JP4284182B2 (ja) 2009-06-24
AR037680A1 (es) 2004-12-01
CA2468649A1 (en) 2003-06-12
JP2008260776A (ja) 2008-10-30
KR20050044593A (ko) 2005-05-12
CN1692116A (zh) 2005-11-02
IL161716A0 (en) 2004-09-27
AU2002346503A1 (en) 2003-06-17
ES2336435T3 (es) 2010-04-13
DE60234951D1 (de) 2010-02-11
PE20030665A1 (es) 2003-08-08
EP1448565B1 (de) 2009-12-30
WO2003048165A1 (en) 2003-06-12
HK1063780A1 (en) 2005-01-14
EP1448565A1 (de) 2004-08-25
CA2468649C (en) 2009-03-10

Similar Documents

Publication Publication Date Title
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
DK1283839T3 (da) Adenosin A2a-receptorantagonister
ATE317844T1 (de) Adenosine a2a receptor antagonisten
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
HUP0401925A3 (en) A2b adenosine receptor antagonists
DE122011000010I1 (de) N-pyrazol a2a rezeptor agonisten
IS5706A (is) Adenosín A3 viðtakastillar
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE293962T1 (de) Adenosin-rezeptor modulatoren
HUP0401437A3 (en) Adenosine a3 receptor agonists
ATE335755T1 (de) Antivirale nukleosidderivate
TWI365879B (en) A2b adenosine receptor antagonists
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
NO20020979L (no) Selektive A2B-adenosinreseptorantagonister
ATE477800T1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE394402T1 (de) Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
NO20052866D0 (no) Imidazokinolinderivater som adenosin A3 reseptorligander
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
DE60106974D1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
IS6818A (is) Histamín viðtaka mótlyf
EP1636230A4 (de) A1-adenosinrezeptorantagonisten
EP1295891A4 (de) Nukleosidderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties